Emalex Biosciences Acquired by Teva | Healthcare M&A Deal

Teva has acquired Emalex Biosciences, a pharmacy business in New Jersey, for $700 million. Teva acquisitions add Emalex’s lead investigational therapy ecopipam for pediatric Tourette syndrome, supporting Teva’s neuroscience pipeline and growth strategy. Emalex Biosciences operates in healthcare drug development, with an NDA submission anticipated in 2H 2026 following positive Phase 3 results. The merger acquisition is a public company acquisition under a definitive agreement, with Emalex shareholders receiving $700 million in cash plus up to $200 million in commercial milestone payments and net sales-based royalties, subject to regulatory approval.